greeksoup/ stock research
Stock research / United States / SNY / Year to 31 December 2022

Sanofi (SNY) annual results, year to 31 December 2022: revenue EUR 37,651 million, from the 20-F

Sanofi files a 20-F with the SEC once a year, in euros. In the year to 31 December 2022 it reported revenue from the sale of goods of EUR 37,651 million ($39.7 billion at the year's average rate), down 0.3% on the year before. Its profit attributable to shareholders was EUR 8,371 million, up 34.5%, and diluted earnings per share EUR 6.66.

Revenue
EUR 37,651 million
-0.3% on the year
FY2015FY2022
Operating margin
27.0%
21.5% a year earlier
FY2015FY2022
Net income
EUR 8,371 million
+34.5% on the year
FY2015FY2022
Diluted EPS
EUR 6.66
FY2015FY2022

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2021Dec 2022 †
Revenue from the sale of goods37,76137,651
Cost of sales12,25511,882
Gross profit26,92028,679
Research and development5,6926,501
Selling, general and administrative9,5558,739
Operating profit8,12610,162
Finance costs368430
Income tax1,5581,909
Profit for the year6,2798,484
Profit attributable to shareholders6,2238,371
Filing20-F20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2021Dec 2022 †
Diluted EPSn/a6.66
Basic EPSn/a6.69
Filing20-F20-F

EUR per ordinary share, as filed.

Cash flow

Year toDec 2021Dec 2022 †
Cash from operations10,52210,526
Cash from investing-7,298-2,075
Cash from financing-7,056-5,821
Buybacks382497
Dividends paid4,0084,168
Filing20-F20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2021Dec 2022 †
Funded by
Equity attributable to shareholders68,68174,784
Non-controlling interests350368
Borrowings, as filed20,25019,218
Lease liabilities2,1082,181
Other liabilities28,85330,171
Total equity and liabilities120,242126,722
Owned
Property, plant and equipment10,0289,869
Goodwill48,05649,892
Other intangible assets21,40721,640
Cash and cash equivalents10,09812,736
Inventories8,7158,960
Other assets21,93823,625
Total assets120,242126,722
Filing20-F20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2021Dec 2022 †
Return on year-end equity9.1%11.2%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2022, filed 13 February 2025: the filing. The figures are in euros as filed.